Ads
related to: poorly differentiated adenocarcinoma lung prognosis- Treatment Modifications
View Treatment Modifications
To Manage Adverse Reactions.
- View All Indications
Explore All Indications And See
The Range Of Treatment Options.
- See Dosing Schedules
Find Dosing Information For This
1L NSCLC Dual I-O Option Today.
- Prep & Admin
Preparation & Administration For
Lung Cancer Immunotherapy.
- Explore Patient Programs
Visit Access And Support Site
& View Resources For Your Patients.
- Review Clinical Data
Explore Efficacy & Safety Info
For This Treatment Option.
- Treatment Modifications
Search results
Results From The WOW.Com Content Network
Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer, it is characterized by distinct cellular and molecular features. [1] It is classified as one of several non-small cell lung cancers (NSCLC), to distinguish it from small cell lung cancer which has a different behavior and prognosis.
Nearly 40% of lung cancers are adenocarcinomas, which usually originates in peripheral lung tissue. [10] Most cases of adenocarcinoma are associated with smoking; however, among people who have smoked fewer than 100 cigarettes in their lifetimes ("never-smokers"), [11] adenocarcinoma is the most common form of lung cancer. [12]
[5] [6] Survival is significantly better in patients whose tumors are well differentiated (i.e. the glands and/or tubules are more completely developed) than when poorly differentiated (i.e. with rudimentary glands). [7] Some studies suggest that the oncogenes H-ras and fes are important drivers of oncogenesis in many acinar-type lung cancers. [8]
Pemetrexed has been shown to improve survival in non-squamous cell NSCLC, and is the first drug to reveal differential survival benefit in large cell lung carcinoma. [7] [71] C-SCLC appear to express female hormone (i.e. estrogen and/or progesterone) receptors in a high (50–67%) proportion of cases, similar to breast carcinomas. [72]
The histologic tumor grade score along with the metastatic (whole-body-level cancer-spread) staging are used to evaluate each specific cancer patient, develop their individual treatment strategy and to predict their prognosis. A cancer that is very poorly differentiated is called anaplastic.
The incidence of bronchiolo-alveolar carcinoma has been reported to vary from 4–24% of all lung cancer patients. [23] An analysis of Surveillance epidemiology and End results registry ( SEER) by Read et al. revealed that although the incidence of BAC has increased over the past two decade it still constitutes less than 4% of NSCLC in every ...
Ad
related to: poorly differentiated adenocarcinoma lung prognosis